Agreements

Date: 2017-07-31

Type of information: Product acquisition

Compound: Bruton's tyrosine kinase (BTK) inhibitor program including LOXO-305 (formerly RXC005)

Company: Loxo Oncology (USA - CT) Redx Pharma (UK)

Therapeutic area: Cancer - Oncology

Type agreement: product acquisition

Action mechanism: Bruton's tyrosine kinase (BTK) inhibitor/tyrosine kinase inhibitor. LOXO-305 was designed to reversibly bind Bruton's tyrosine kinase and preserve activity in the presence of the C481S acquired resistance mutation. Additionally, it was designed to avoid off-target kinases that have complicated the development of both covalent and reversible BTK inhibitors, such as EGFR, BMX, TEC, ITK, BLK, LCK and SRC.

Disease:

Details: • On July 31, 2017, Loxo Oncology announced that the company has entered into a definitive agreement to purchase the Bruton's tyrosine kinase (BTK) inhibitor program from Redx Pharma. The lead candidate from this program LOXO-305  is expected to enter clinical development in 2018. It will be entering studies in the coming months to enable submission of an Investigational New Drug (IND) application in 2018.

Financial terms:

• Under the terms of the agreement, Loxo Oncology has made a $40M payment to Redx Pharma Plc for the full acquisition of the BTK discovery program, including lead candidate LOXO-305 (formerly RXC005). Loxo Oncology is not subject to milestone or royalty obligations.

Latest news:

Is general: Yes